

High-throughput sequencing of *16S rDNA* amplicons characterizes bacterial composition in cerebrospinal fluid samples from patients with purulent meningitis

Aicui Liu^{1,2,*}
Chao Wang^{1,2,*}
Zhijuan Liang³
Zhi-Wei Zhou⁴
Lin Wang^{1,2}
Qiaoli Ma^{1,2}
Guowei Wang^{1,2}
Shu-Feng Zhou⁴
Zhenhai Wang^{1,2}

¹Neurology Center, General Hospital of Ningxia Medical University, Yinchuan, Ningxia; ²Key Laboratory of Brain Diseases of Ningxia, Yinchuan, Ningxia; ³Department of Neurology, The First People's Hospital of Lanzhou, Lanzhou, Gansu, People's Republic of China; ⁴Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL, USA

*These authors contributed equally to this work

Correspondence: Zhenhai Wang
Neurology Center, General Hospital of Ningxia Medical University, Key Laboratory of Brain Diseases of Ningxia, 804 Shengli Street, Yinchuan, Ningxia 750004, People's Republic of China
Tel +86 951 674 4205
Fax +86 951 408 2981
Email 13995089189@163.com

Shu-Feng Zhou
Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, 12901 Bruce B Downs Boulevard, Tampa, FL 33612, USA
Tel +1 813 974 6276
Fax +1 813 905 9885
Email szhou@health.usf.edu

Abstract: Purulent meningitis (PM) is a severe infectious disease that is associated with high rates of morbidity and mortality. It has been recognized that bacterial infection is a major contributing factor to the pathogenesis of PM. However, there is a lack of information on the bacterial composition in PM, due to the low positive rate of cerebrospinal fluid bacterial culture. Herein, we aimed to discriminate and identify the main pathogens and bacterial composition in cerebrospinal fluid sample from PM patients using high-throughput sequencing approach. The cerebrospinal fluid samples were collected from 26 PM patients, and were determined as culture-negative samples. The polymerase chain reaction products of the hypervariable regions of *16S rDNA* gene in these 26 samples of PM were sequenced using the 454 GS FLX system. The results showed that there were 71,440 pyrosequencing reads, of which, the predominant phyla were Proteobacteria and Firmicutes; and the predominant genera were *Streptococcus*, *Acinetobacter*, *Pseudomonas*, and *Neisseria*. The bacterial species in the cerebrospinal fluid were complex, with 61.5% of the samples presenting with mixed pathogens. A significant number of bacteria belonging to a known pathogenic potential was observed. The number of operational taxonomic units for individual samples ranged from six to 75 and there was a comparable difference in the species diversity that was calculated through alpha and beta diversity analysis. Collectively, the data show that high-throughput sequencing approach facilitates the characterization of the pathogens in cerebrospinal fluid and determine the abundance and the composition of bacteria in the cerebrospinal fluid samples of the PM patients, which may provide a better understanding of pathogens in PM and assist clinicians to make rational and effective therapeutic decisions.

Keywords: Bioinformatics, cerebrospinal fluid sample, OTU

Introduction

Meningitis is a clinical syndrome featured with inflammation of the meninges that cover the brain and spinal cord, resulting in high morbidity and mortality rates.^{1,2} It was estimated that meningitis resulted in 420,000 deaths in 2010 and this disease killed 303,000 people in 2013 globally.³ The causes of meningitis include bacteria, viruses, fungi, parasites, drugs, chemical irritation, subarachnoid hemorrhage, cancer and other conditions. Viral meningitis is the most common type of meningitis and is often less severe than bacterial meningitis. Bacterial meningitis is often severe that represents the most significant contributor to the mortality and morbidity.^{4,5} Some of the leading causes of bacterial meningitis include *Haemophilus influenzae* (most often caused by type b, Hib), *Streptococcus pneumoniae*, group B *Streptococcus*, *Listeria*

monocytogenes, and *Neisseria meningitidis*. The incidence of bacterial meningitis significantly varies worldwide, due to differences in the specific etiologic agents and access to medical resources. In US, an estimated 4,100 new cases (ie, 1.33/100,000) and 500 deaths from bacterial meningitis occurred annually during 2003–2007.⁶ There are about 3,200 people suffering from bacterial meningitis in the UK each year. The estimated annual incidence (per 100,000 population) of probable bacterial meningitis ranged from 1.84 to 2.93 for the entire population and from 6.95 to 22.30 for children aged <5 years in People's Republic of China.⁷ It is speculated that the incidence of bacterial meningitis is ten times higher in the developing countries than that in developed countries, in particular, in Niger, Nigeria, Burkina Faso, Chad, and Mali. Purulent meningitis (PM) is the most serious infectious diseases caused by bacteria in the central nervous system. It has been reported that the average mortality due to PM was higher than 20%.^{8,9} Particularly, the mortality reaches to 35%–36% in some African countries, and approximately 30%–50% of the PM survivors experience permanent neurological sequelae including epilepsy, hydrocephalus, hearing loss, learning and behavioral difficulties, as well as decreased intelligence.^{10–12} Thus, it is important to develop new and more efficacious therapy for PM treatment.

Given the complexity of the pathogens of PM, identification of pathogenic microbes is critical for selecting optimal therapy to reach maximum therapeutic effect in the treatment of PM in clinical practice. It has been showed that *H. influenzae*, *L. monocytogenes*, *N. meningitidis*, *Streptococcus agalactiae* (group B *Streptococcus*), and *S. pneumoniae* are the most common etiologic bacteria.^{1,13} Currently, the cerebrospinal fluid bacterial culture is the golden standard for the diagnosis of PM and the culture-based methods do provide a good reference for clinicians; however, the current diagnostic approaches are incapable of unveiling the full spectrum of the causative pathogens of PM due to the limitations,^{14,15} which include false negative results in the culture specimens because of application of antibiotics, infections with slow-growing, fastidious, and inert microorganisms, and suppression of non-competitive bacteria growth by the secretions from the competitive bacteria when they are co-cultured.^{16,17} Moreover, pathogens like *Tropheryma whippelii*, *Bartonella henselae*, and Bayesian *Rickettsia* are considerably difficult to culture, thus, they may escape from the screening using culture-based method.^{18,19} Due to the limitations of the current cerebrospinal fluid bacterial culture-based method, the full spectrum of the pathogens in cerebrospinal fluid specimens of PM patients cannot be presented, which will jeopardize the therapeutic

outcome in the treatment of PM in clinical practice. Thus, it requires advanced methods to detect the full array of pathogens in cerebrospinal fluid specimens of PM patients to avoid the compromise of therapy and achieve maximum therapeutic outcome in clinical practice.

Increasing evidence shows that *16S rDNA* gene sequencing approach is able to identify fast and accurately the bacteria because it can overcome the limitations of culture-based bacterial detection method.^{20,21} With advances in sequencing technology, the feasibility of *16S rDNA* analysis using 454 GS FLX system has already been proven in the research of microbiota in the oral cavity, wound, urine, and gastrointestinal tract, and sufficient data generated by 454 GS FLX system make it possible to analyze the diversity of the bacterial communities.^{22–28} Such a sequencing approach can provide a global view of the bacterial flora; however, *16S rDNA* gene sequencing has not been used to identify the bacteria in cerebrospinal fluid samples of PM patients. In this study, we collected the cerebrospinal fluid samples from the PM patients, which were the most valuable sample reflecting the main part of the bacterial communities in the central nervous system, and we aimed to investigate the complex of bacterial communities in the cerebrospinal fluid in patients with culture-negative PM using *16S rDNA* Amplicon 454 pyrosequencing.

Materials and methods

Patients

Twenty-six patients from the General Hospital of Ningxia Medical University were enrolled in the present study. All patients were confirmed as PM according to the clinical criteria provided by the China Health Ministry Guidelines. Clinical signs and symptoms of PM included fever, severe headache, neck stiffness, vomit, seizures, and/or rash (Table 1). All patients were tested for lumbar puncture according to the diagnosis standard for PM and were fully informed of the risks and potential benefits of the cerebrospinal fluid examination. Consent forms were obtained from all enrolled PM patients. The protocol was approved by the Ethics Committee of the General Hospital of Ningxia Medical University. All procedures were conducted in accordance with the criteria of the Declaration of Helsinki.

Cerebrospinal fluid sampling

The cerebrospinal fluid was collected by a lumbar puncture through the L3/L4 or L4/L5 intervertebral space. All the cerebrospinal fluid samples were immediately stored in a sterile container. Then, the cerebrospinal fluid samples were aliquot

Table 1 The clinical data of 26 culture-negative cerebrospinal fluid samples with bacterial PCR positive

Sample ID	Age (years)	Main symptom	Peripheral blood [#]		First cerebral spinal fluid test after hospitalization			Hospital stay (days)	Prognosis			
			WBC ^a (10 ⁹ /L)	N ^b (%)	Time ^c (days)	WBC ^d (/mm ³)	N ^e (%)			Pro ^f (g/L)	Glu ^g (mmol/L)	Cl ^h (mmol/L)
3	59	Fever, headache, nausea	15.45	80.1	4	1,250	79	1,970	3.0	115.1	18	Disease cured
4	28	Fever, fatigue	11.88	78.2	1	1,100	81	1,680	2.1	121.0	26	Disease cured
5	31	Fever, headache	7.15	74.7	1	610	73	2,410	1.6	113.9	28	Symptoms relieved
6	4	Fever, cough	10.32	73.9	1	2,670	96	0,240	3.7	123.7	9	Symptoms relieved
12	36	Fever, headache	13.55	88.5	2	8,160	90	5,780	1.1	112.6	87	Disease cured
16	21	Unconsciousness	10.15	71.6	1	1,800	96	1,970	1.1	120.2	14	Disease cured
19	41	Fever	13.35	87.4	7	1,100	80	0,710	2.5	118.0	62	Symptoms relieved
23	45	Fever, headache	17.74	82.4	2	880	88	2,760	1.1	103.0	35	Symptoms relieved
24	4	Fever, nausea	11.02	80.4	1	2,500	87	1,390	1.1	105.5	7	Symptoms relieved
25	15	Headache	4.46	67.5	1	550	74	2,360	2.01	114.0	45	Symptoms relieved
Y1	41	Headache	10.82	77.3	1	5,500	85	2,340	1.9	125.6	9	Symptoms relieved
Y2	30	Fever, headache	13.95	82.3	5	850	67	5,910	6.1	123.1	12	Symptoms relieved
Y3	43	Headache	10.38	79.6	3	1,080	70	0,750	3.4	121.8	17	Symptoms relieved
Y4	59	Fever	13.93	84.1	1	510	78	0,950	2.4	123.5	15	Disease cured
Y5	23	Fever, headache	7.43	84.7	2	640	73	1,270	1.1	119.8	10	Disease cured
Y6	28	Headache, nausea	12.70	84.6	1	3,500	85	1,570	1.07	122.0	35	Disease cured
Y7	54	Headache, nausea	10.78	87.7	1	1,800	81	6,140	2.2	101.2	3	Symptoms not relieved/ disease not cured
Y8	64	Fever	9.86	88.8	5	1,150	87	0,870	3.7	125.5	23	Disease cured
Y9	20	Fever, headache	7.34	79.0	1	750	74	2,390	1.2	112.1	22	Symptoms relieved
Y10	24	Fever, headache	12.86	73.0	1	980	77	1,070	1.6	120.3	34	Symptoms relieved
Y11	63	Headache	12.52	82.7	1	8,000	88	2,530	6.0	133.5	4	Symptoms not relieved/ disease not cured
Y12	42	Fever, headache	13.68	82.2	2	1,440	83	1,460	2.9	118.3	15	Symptoms relieved
Y13	39	Headache	11.93	86.4	5	1,360	89	7,240	1.1	106.1	64	Symptoms relieved
Y14	38	Fever, headache	8.17	77.9	6	500	72	1,640	2.12	120.0	31	Symptoms relieved
Y15	57	Headache, nausea	10.59	85.1	1	1,300	77	0,610	3.59	122.0	27	Symptoms relieved
Y16	39	Fever, headache	11.64	75.5	1	890	85	1,330	2.14	110.0	18	Symptoms relieved

Notes: [#]Peripheral blood test before hospitalization. ^aWhite blood cells count of peripheral blood; ^bneutrophils count of peripheral blood; ^ctime of sampling first cerebral spinal fluid after hospitalization; ^dwhite blood cells count of cerebral spinal fluid; ^eneutrophils count of cerebral spinal fluid; ^fprotein contents of cerebral spinal fluid; ^gglucose contents of cerebral spinal fluid; ^hchloride contents of cerebral spinal fluid.

Abbreviations: PCR, polymerase chain reaction; WBC, white blood count; Pro, protein; Glu, glucose.

into 1.5 mL sterile Eppendorf tubes and stored at -80°C for subsequential assays. All specimens were culture-negative, which were examined in the clinical laboratory in General Hospital of Ningxia Medical University. Collection and transportation of specimens were strictly in accordance with the sterile operating procedures.

DNA extraction and quantity detection

DNA was isolated from cerebrospinal fluid using a QIAamp DNA Micro Kit (Qiagen NV, Venlo, the Netherlands). A quota of 1 mL of cerebrospinal fluid was transferred into a 1.5 mL microcentrifuge tube and centrifuged at $8,000\times g$ for 15 minutes. The supernatant was decanted and the pellet was resuspended in the remaining solution. Then the samples were resuspended in phosphate-buffered saline containing lysozyme and lysostaphin at concentrations of 5 mg/mL and 32 U/mL, respectively. The mixture solution was incubated for 2 hours at 37°C . Following that, a volume of 20 μL proteinase K and 200 μL Buffer AL that were provided in the QIAamp DNA Micro Kit were added and incubated for 1 hour at 56°C . After the incubation, the DNA purification was performed according to the manufacturer's instructions. The DNA concentration was measured by UV spectrophotometer at 260 nm. The average DNA concentration of the samples was 22.8 ng/mL.

Barcoded primer design

The polymerase chain reaction (PCR) enrichment of the *16S rDNA* V3–V5 hypervariable region was performed using the forward primer: 5'-CCATCTCATCCCTGCGTG TCTCCGACTCAGACGAGTGCGTCCGTC AATTCMT TTGAGTTT-3' and the reverse primer: 5'-CCTATCCCC TGTGTGCCTTGGCAGTCTCAGACTCCTACGGGAG GCTCTACGGGAGGCAGCAG-3'. For aforementioned primers, the 5'-terminal of each primer contained a ten-base-oligonucleotide tag, while the sequence after the hyphen was able to pair with the sequences of the end region. The 26 pairs of primers that contained 26 different ten-base-oligonucleotides and identical following sequences were used to perform the subsequential PCR enrichment. The barcoded primers were synthesized by Shanghai Sangon Biological Engineering Technology & Service Co., Ltd. (Shanghai, People's Republic of China).

PCR enrichment of the V3–V5 region and pyrosequencing with the 454 platform

The extracted DNA from 26 cerebrospinal fluid samples was used as a template for PCR amplification by the V3–V5 primers. Each PCR reaction system was comprised of 12.5 μL

PCR master Mix (Dream Taq PCR Master Mix, Fermentas, Burlington, Canada), 0.5 μL forward primer, 0.5 μL reverse primer, 1 μL template DNA and 10.5 μL nuclease-free water. Touchdown PCR conditions were as follows: initial denaturation for 5 minutes at 95°C , denaturation for 30 seconds at 95°C , annealing for 30 seconds at 56°C , and extension for 30 seconds at 72°C . Samples were stored at -20°C after the reaction. The pooled tagged single-stranded pyrosequencing library underwent emPCR and pyrosequencing using a Roche 454 GS FLX Pyrosequencer (Roche Life Sciences Inc., Basel, Switzerland) according to the manufacturer's instructions.

Bioinformatic analysis

The high-throughput pyrosequencing reads were reassigned to samples according to barcodes. Sequences were clustered into operational taxonomic units (OTUs). The OTUs that reached 97% similarity level were used for alpha diversity analysis that analyzed the species diversity in the single sample by the evaluation of abundance-based coverage estimators, Chao1, Shannon, and Simpson parameters; and the rarefaction curve was also analyzed using the Mothur software v1.27.0 program.^{29–32} Following this, taxonomy-based analyses were performed through the classification of each sequence using the Naïve Bayesian classifier program in Ribosomal Database Project (RDP) database at the Center for Microbial Ecology in Michigan State University (<http://rdp.cme.msu.edu/>; East Lansing, MI, USA).^{31,32} The confidence level was of 95%. The sequences were assigned until the genus level in bacteria domain was collected and screened.^{29–32} Each of the reads was assigned a phylum, class, family, and genus. The taxonomic assignment was unambiguous within an 80% confidence threshold, which has been estimated to taxonomically assign reads with over 98% accuracy at genus level. Furthermore, the beta diversity analysis was performed to assess the distribution and content of bacteria and evaluate the total diversity in different samples based on the bacterial profile. Sequences were clustered at 97% nucleotide identity over 90% sequence alignment length using the Mothur software. For this analysis, sequences over 97% identical were considered to correspond to the same OTUs, representing a group of reads which likely belong to the same species.³³

Results

High-throughput sequencing reveals 71,440 pyrosequencing reads

First, we performed the high-throughput sequencing to examine the possible bacterial DNA sequences in 26 culture-negative cerebrospinal fluid samples. As shown in Table 2,

Table 2 Sampling depth found by 454 sequencing from 26 culture-negative cerebrospinal fluid samples

Sample ID	Raw tag number ^a	Final tag number ^b	OTU ^c number	Phyla ^d (6)	Genera ^e (62)
I2	8,804	2,263	28	3	11
I6	12,120	6,658	31	3	16
I9	9,981	2,814	8	1	2
I23	10,174	4,931	39	3	13
I24	10,296	5,736	6	2	4
I25	10,705	4,508	75	5	23
I3	10,637	6,400	7	2	4
I4	6,691	3,465	13	2	6
I5	15,619	4,382	25	2	6
I6	7,837	3,308	15	2	6
Y1	3,915	910	7	1	4
Y10	4,549	2,164	45	2	23
Y11	7,099	3,344	51	2	20
Y12	5,627	2,419	67	4	33
Y13	3,568	1,596	53	2	27
Y14	2,546	1,506	3	2	3
Y15	5,053	2,477	42	3	22
Y16	7,795	3,212	44	2	15
Y2	1,565	521	47	3	22
Y3	3,137	1,223	39	2	18
Y4	1,237	638	36	2	23
Y5	3,549	1,730	44	2	18
Y6	1,306	443	26	2	19
Y7	4,242	1,001	33	2	19
Y8	4,820	2,788	8	2	5
Y9	2,522	1,003	41	2	3

Notes: ^aThe total number of reads per dataset before removing sequences of insufficient quality; ^bthe number of reads per dataset after removing sequences of insufficient quality and used for the actual analysis; ^cOTUs, operational taxonomic units at 3% nucleotide difference; ^dthe number of phyla detected in every sample and the total number of phyla detected in parenthesis; ^ethe number of genera detected in every sample and the total number of genera detected in parenthesis.

Abbreviation: OTU, operational taxonomic unit.

there were a total of 71,440 pyrosequencing reads which were obtained from the 26 culture-negative cerebrospinal fluid samples. The sequences with insufficient quality or sequences that could not be adequately assigned were not included, such as chimera sequences and a small amount of nontarget sequences. For the identified the pyrosequencing reads, the average length of the sequences was 550 bp after trimming the primers. Taken together, the high-throughput sequencing approach shows an ability for identifying the bacterial DNA sequences from culture-negative cerebrospinal fluids of patients with PM, which may be clinically helpful for the treatment of PM.

Identification of the bacteria found in culture-negative cerebrospinal fluid samples from patients with PM

Following the sequencing, these pyrosequencing reads were classified using the RDP classifier at a confidence level of 95% and assigned taxonomic classifications to the sequences for biological analysis. The tag sequences of the identified DNA in 26 culture-negative cerebrospinal fluid samples

were compared using the RDP database to annotate species. The data showed that most of bacterial reads were assigned to genus level and a small number of bacterial reads were assigned to species level.

As shown in Figures 1 and 2, the sequences provided an overview of pathogens in the 26 cerebrospinal fluid samples. At phylum level, there were six known phyla which were identified in the cerebrospinal fluid samples, including Proteobacteria, Firmicutes, Bacteroidetes, Fusobacteria, Deinococcus-Thermus, and Actinobacteria (Figure 1A and B). Proteobacteria and Firmicutes were widely distributed and predominated among the pathogens in the 26 cerebrospinal fluid samples from patients with PM (Figure 1A and B). At genus level, these sequences represented 62 different genera, of which, there was a high abundance of 16 genera (Figure 2). The top five genera with the most abundance of sequences were *Streptococcus*, *Acinetobacter*, *Pseudomonas*, *Neisseria*, and *Sphingomonas* (Figure 2A); and the top five most widely distributed genera were *Streptococcus*, *Acinetobacter*, *Limnohabitans*, *Sphingomonas*, and *Pseudomonas* (Figure 2B). The data were comparable to those previously




Figure 1 Bacterial community composition of 26 culture-negative cerebrospinal fluid samples from patients with purulent meningitis (PM) at phylum level.

Notes: This figure shows the bacterial community composition of each sample at phylum level. **(A)** The vertical axis represents relative bacterial abundance of corresponding phylum. The horizontal axis represents 26 culture-negative cerebrospinal fluid samples. Different color components represent different phylum. Taxonomic name of higher abundance is shown in these charts; those that failed to meet the lower abundance is assigned the label "Others". "Unknown" indicates that the taxonomy level is unable to be defined according to the corresponding abundance. **(B)** The vertical axis represents the number of samples and the horizontal axis represents phylum of bacterial. There were six phyla in 26 culture-negative cerebrospinal fluid samples, including Proteobacteria, Firmicutes, Bacteroidetes, Fusobacteria, Deinococcus-Thermus, and Actinobacteria. Among these Firmicutes and Proteobacteria were widely distributed.

reported (Table 3). Of note, the data showed that the dominant pathogenic microorganism was *Streptococcus* which presented in 84.6% single infection or mixed infection samples. Moreover, 16 out of 26 (61.5%) samples presented mixed pathogens (Figure 2) and *Acinetobacter* and *Pseudomonas* were the most frequent combinational pathogens that were present in the 26 cerebrospinal fluid samples from patients with PM. In addition, a part of the sequences represented uncultured bacteria and many of them belonged to unknown pathogenic potential (Figure 2). Taken together, there are a variety of pathogens that were present in the culture-negative cerebrospinal fluid, which might be involved in the pathogenesis of PM. The identification and classification of pathogens in patients with PM can facilitate the optimization of the therapy and improve clinical outcomes.

Species richness and diversity estimation of microbiota in the culture-negative cerebrospinal fluid samples from PM patients

Furthermore, we performed a bioinformatic analysis of the large number of pyrosequencing reads to evaluate the species richness and diversity of microbiota in the culture-negative cerebrospinal fluid samples. These reads clustered into 413 OTU at a 97% similarity level. Based on the OTU data, we further calculated alpha diversity. The indices of bacterial richness and diversity of OTUs at a 3% sequence dissimilarity level are summarized in Table 4. Alpha diversity indicated

that each culture-negative cerebrospinal fluid sample contained low number of OTU, which means it has relatively low diversity in the cerebrospinal fluid sample compared with other environmental species (Table 4). Moreover, the richness of bacterial communities in culture-negative cerebrospinal fluid sample was estimated as presented by the rarefaction curve. The trend of the rarefaction curves also confirmed that there was low richness in culture-negative cerebrospinal fluid sample and the saturated shape of the rarefaction curves indicated that bacterial richness of cerebrospinal fluid sample was completely sampled (Figure 3).

Furthermore, in order to evaluate the total diversity and assess the distribution and content of bacteria in 26 cerebrospinal fluid samples from patients with PM, the beta analysis was performed. As shown in Figure 4A and B and Figure 5A–F, there was substantial difference in the species distribution in the 26 cerebrospinal fluid samples from patients with PM. The beta diversity of 26 culture-negative cerebrospinal fluid samples was indicated by Whittaker index that was used to evaluate the species difference in diversity between different samples. The higher index indicates more difference. The pathogens from number 3 sample showed the most different diversity from other samples (Figure 4A). According to the Ward analysis data, there were two clusters which can be further divided into seven subclusters (Figure 4B). In addition, the total diversity and distribution of bacteria in 26 cerebrospinal fluid samples from patients with PM were evaluated by weighted- and unweighted-UniFrac index (Figure 5A–F)




Figure 2 Bacterial community composition of 26 culture-negative cerebrospinal fluid samples from patients with PM at genus level.

Notes: This figure shows bacterial community composition of each sample at genus level. **(A)** The vertical axis represents relative bacterial abundance of corresponding phylum. The horizontal axis represents 26 culture-negative cerebrospinal fluid samples. Different color components represent different genus. Taxonomic name of higher abundance is shown in these charts, those failed to meet the lower abundance was assigned the label "Others". "Unknown" indicates that the taxonomy level is unable to be defined according to the abundance. **(B)** The vertical axis represents the number of samples and the horizontal axis represents genus of bacterial. There were 16 major genera and much mixed infection in 26 culture-negative cerebrospinal fluid samples. The top five most widely distributed genera were *Streptococcus*, *Acinetobacter*, *Limnohabitans*, *Sphingomonas*, and *Pseudomonas*.

Abbreviation: PM, purulent meningitis.

Table 3 The first three causative pathogens in culture-negative cerebrospinal fluid samples from patients with PM

References	Sampling region	Sampling time (year)	Test method	Species level	Causative pathogen	First (%)	Second (%)	Third (%)
Present study	People's Republic of China	2010–2012	Metagenomic	Genus	<i>Streptococcus</i> (84.6)		<i>Acinetobacter</i> (76.9)	<i>Pseudomonas</i> (57.7)
Parda and Polkowska ⁴⁰	Poland	2010–2011	Culture	Species	<i>Streptococcus pneumoniae</i> (21.3)		<i>N. meningitidis</i> (17.3)	<i>H. influenzae</i> type b (0.1)
Butsashvili et al ⁴¹	Georgia	2001–2010	Culture	Species	<i>S. pneumoniae</i> (52.8)		<i>H. influenzae</i> (13.4)	<i>Neisseria</i> (12.6)
Dzupová et al ⁴²	Czech Republic	1997–2006	Culture	Species	<i>S. pneumoniae</i> (28.0)		<i>Neisseria</i> (25.0)	Unknown (24.0)
Azevedo et al ⁴³	Brazil	2000–2010	Culture and PCR	Species	<i>Neisseria meningitidis</i> (31.7)		<i>S. pneumoniae</i> (12.0)	<i>H. influenzae</i> type b (2.0)
Mendsaikhan et al ⁴⁴	Mongolia	2002–2004	Culture and PCR	Species	<i>Haemophilus influenzae</i> type b (41.0)		<i>Meningococcal</i> (19.1)	<i>Pneumococcal</i> (16.2)
Thigpen et al ⁶	US	2003–2007	Culture	Species	<i>S. pneumoniae</i> (58.0)		<i>Group B Streptococcus</i> (18.1)	<i>N. meningitidis</i> (13.9)
Teleb et al ⁴⁵	Mediterranean	2005–2010	Culture	Species	<i>S. pneumoniae</i> (27.0)		<i>N. meningitidis</i> (22.0)	<i>H. influenzae</i> (10.0)
Centers for Disease Control and Prevention ⁴⁶	Africa	2002–2008	Culture	Species	<i>S. pneumoniae</i> (47.0)		<i>H. influenzae</i> (34.0)	<i>N. meningitidis</i> (19.0)
Dash et al ⁴⁷	Oman	2000–2005	Culture and latex agglutination	Species	<i>H. influenzae</i> (22.0)		<i>S. pneumoniae</i> (15.0)	<i>S. pneumoniae</i> (11.0)
Kajjalainen et al ⁴⁸	Russia	2001–2003	Culture and RAL	Species	<i>N. meningitidis</i> (66.0)		<i>H. influenzae</i> (19.0)	<i>S. pneumoniae</i> (16.0)
Cho et al ⁴⁹	Korea	1996–2005	Culture	Species	<i>Streptococcus agalactiae</i> (24.6)		<i>S. pneumoniae</i> (22.6)	<i>H. influenzae</i> (16.7)
Pérez et al ⁵⁰	Cuba	1998–2007	Culture and PCR	Species	<i>S. pneumoniae</i> (23.6)		<i>N. meningitidis</i> (8.2)	<i>H. influenzae</i> (6.0)

Abbreviations: PCR, polymerase chain reaction; PM, purulent meningitis; RAL, rapid antigen latex agglutination.

Table 4 Comparison of phylotype richness and diversity estimation at 3% dissimilarity from the pyrosequencing analysis

Sample ID	OTU number	Chao ^a	ACE ^a	Shannon ^b	Simpson ^b
12	28	73.33	221.98	0.83	0.61
16	31	48.50	63.71	1.39	0.34
19	8	11.33	16.75	0.03	0.99
23	39	75.14	192.11	1.27	0.41
24	6	7.00	11.88	0.07	0.98
25	75	141.23	164.20	1.96	0.23
3	7	7.33	8.36	0.02	1.00
4	13	41.00	107.40	0.43	0.81
5	25	43.20	52.46	0.73	0.57
6	15	18.00	24.61	0.67	0.62
Y1	7	10.00	31.61	0.10	0.97
Y10	45	70.67	120.86	0.77	0.73
Y11	51	99.33	111.07	0.52	0.84
Y12	67	88.94	126.58	1.83	0.31
Y13	53	99.43	98.82	1.62	0.37
Y14	3	3.00	4.00	0.02	1.00
Y15	42	59.00	86.22	1.22	0.41
Y16	44	59.83	62.39	0.73	0.70
Y2	47	75.11	77.14	2.26	0.21
Y3	39	91.50	145.96	1.36	0.49
Y4	36	51.00	65.73	1.41	0.49
Y5	44	94.60	114.04	0.88	0.70
Y6	26	48.50	52.78	2.24	0.15
Y7	33	56.75	142.47	0.46	0.87
Y8	8	8.25	9.33	0.09	0.97
Y9	41	110.00	356.73	2.14	0.19

Notes: ^aChao and ACE were used to estimate species richness; ^bShannon index and Simpson index are diversity indexes. Shannon index is larger and Simpson index closer to 0. It means that the more abundant species in the sample.

Abbreviations: ACE, abundance-based coverage estimators; OTU, operational taxonomic unit.

which showed similar results to that of Whittaker index. Collectively, the results show a comparable difference in the diversity of species distribution and evolution in the 26 cerebrospinal fluid samples from patients with PM.

Discussion

Due to the significant morbidity and mortality resulting from PM, it is important to characterize the cause of PM for the optimization of the treatment of PM in clinical practice. The complex of the pathogen-induced PM remains a major challenge for the use of current therapeutics. Advances in the characterization and identification of the bacteria have facilitated the uncovering of the global view of causative pathogens of PM. Metagenomic studies have dramatically expanded our knowledge of the microbial world without the cultivation of microorganisms and can overcome the shortage of the culture-based approach.^{28,29,31,32,34} In the present study, we have performed metagenomics high-throughput sequencing to analyze the pathogens present in 26 cerebrospinal fluid samples from




Figure 3 Rarefaction curves of 26 culture-negative cerebrospinal fluid samples from patients with PM.

Notes: Rarefaction curves were used to estimate whether the amount of sequenced sample is sufficient to cover all species and estimate species richness (in this case the number of taxa at a 3% dissimilarity level) among 26 culture-negative cerebrospinal fluid samples. The vertical axis shows the number of OTUs that would be expected to be found after sampling the numbers of tags shown on the horizontal axis. Lines of different colors represent 26 culture-negative cerebrospinal fluid samples, respectively. The saturated shapes of the rarefaction curves indicate that sequencing depth has covered all species in the sample. The unsaturated shapes of the rarefaction curves indicate that bacterial richness of the sample is high and there are many undetected species.

Abbreviations: PM, purulent meningitis; OTUs, operational taxonomic units.

PM patients based on complete quantitative analysis. We have identified most of the bacterial pathogens in 26 culture-negative cerebrospinal samples from patients with PM. The percentage of sequences belonging to each bacterial

genus has been calculated for every patient, which can facilitate the choice of therapy for the PM treatment, in order to achieve the optimal therapeutic outcome in clinical practice.




Figure 4 Beta diversity of 26 culture-negative cerebrospinal fluid samples from patients with PM indicated by Whittaker index.

Notes: Whittaker index was used to evaluate the difference in species diversity between different samples. The higher index indicates more difference. (A) The Whittaker index of species distribution of 26 cerebrospinal fluid samples from patients with PM. (B) The cluster dendrogram based on Whittaker index analyzed by Ward of hclust in R program.

Abbreviations: PM, purulent meningitis; hclust, hierarchical clustering.




Figure 5 Beta diversity of 26 culture-negative cerebrospinal fluid samples from patients with PM indicated by UniFrac index. **Notes:** UniFrac index was used to evaluate the difference in species evolution between different samples. The higher index indicates more difference. **(A)** The weighted-UniFrac index of species distribution of 26 cerebrospinal fluid samples from patients with PM. **(B)** The PCoA analysis of weighted-UniFrac for 26 cerebrospinal fluid samples from patients with PM. **(C)** The cluster dendrogram based on weighted-UniFrac distance analyzed by Ward of hclust in R program. **(D)** The unweighted-UniFrac index of species distribution of 26 cerebrospinal fluid samples from patients with PM. **(E)** The PCoA analysis of unweighted-UniFrac for 26 cerebrospinal fluid samples from patients with PM. **(F)** The cluster dendrogram based on unweighted-UniFrac distance analyzed by Ward of hclust in R program. **Abbreviations:** PCoA, principal coordinates analysis; PM, purulent meningitis; hclust, hierarchical clustering.

Given the complex of pathogens in the development of PM, it is of great importance to identify the composition of the causative pathogens at different levels which is clinically helpful for the proper therapeutics selection and optimization of therapy in the treatment of PM. *Streptococcus* is proposed to be the most dominant causative pathogen of PM. *S. pneumoniae* is commensal colonizer of the nasopharyngeal cavity and a damaged mucosal barrier allows direct invasion from the pharynx into the meninges, which in turn can cause PM.^{33,35} In agreement with previous studies, our findings have shown that the most prevalent representative sequence belonged to *Streptococcus* and that *Streptococcus* was most widely distributed with a proportion of 84.6%. At phylum level, our observations have shown six known phyla, including Proteobacteria, Firmicutes, Bacteroidetes, Fusobacteria, Deinococcus-Thermus, and Actinobacteria using 16S rDNA gene sequencing approach. Of note, the present study has shown the advantage of 16S rDNA gene sequencing approach over the conventional culture-based method, as evidenced by the numerous pathogens that had been identified from culture-negative cerebrospinal fluid samples.

Increasing evidence shows that multiple pathogens have been implicated in the pathogenesis of infectious diseases, including PM. It has been reported that meningitis was caused by multiple microorganisms.^{36,37} In the present study, the data have shown that 16 out of 26 (61.5%) samples had mixed infection. The combination of *Acinetobacter* and *Pseudomonas* was found most frequently. Notably, this is the first study to report this combination in patients with PM. There is a clear evidence of mixed infectious pathogens in patients with PM that may compromise the therapeutic effect in the treatment of PM in clinical practice. Thus, the mixed infections should be considered by clinicians when choosing the therapy. Although the present study was not able to determine which bacteria species was dominant in mixed infection, it did provide new insight into the treatment of PM in clinical practice.

In addition, we detected sequence of unknown species in 15.4% samples, which might be attributable to the a variety of factors, such as non-homogenous lysis of bacterial cells,²⁴ primer mismatches,³⁸ and the presence of mixed bases in PCR process. These reasons can lead to the failure of the species functional annotation. However, PCR-generated errors are very low.³¹ Therefore, these unknown species may be a new phylotype of unknown genus. In the present study, it provides information of rank order of causative pathogens from the present study and others.

It clearly shows that the first three causative pathogens of PM are different. This discrepancy may due to the following reasons. First, the microbial diversity is different due to the geographical location and living condition. The microbial distribution depends on the environment.³⁹ Second, the age of the patient is different. Lastly, the methodology used to characterize the pathogens of the various studies is different.

Strikingly, evidence indicates that environmental factors, such as allergic and pollution agents, can affect or damage the function or integrity of pharyngeal mucosal barrier and bacteria can directly enter into the meninges from the compromised pharyngeal mucosal barrier. Consequently, the penetrated bacteria through the impaired pharyngeal mucosal barrier can induce the development of PM. Therefore, the causal role of environmental factors in the development of PM cannot be excluded and there might be an interplay between the environmental factors and pathogens contributing to the development of PM. Notably, all the enrolled PM patients in the present study originated from Ningxia, the inland of northwest in People's Republic of China, which is away from the ocean with the semi-arid or arid, windy, and sandy climate. This might be a contributing factor to high morbidity of streptococcal meningitis that was found in the present study.

Of importance, the diversity of bacterial species is crucial for PM therapy selection. The high diversity of the bacteria presents a challenge for PM treatment and it requires individualized therapy to achieve maximum therapeutic effect in clinical practice. In the present study, there is a substantial difference in the pathogen distribution, evolution, and content in the 26 cerebrospinal fluid samples from patients with PM, which indicates a comparable diversity. The high diversity also reflects that the multiple infections are an important contributing factor for the development of PM.

In summary, metagenomics high-throughput sequencing is a clinical practical approach to analyzing the pathogens of PM in culture-negative cerebrospinal fluid, which can overcome the limitations of the regular culture-based method. Also, the mixed infection has been observed in PM. The dominant genus is *Streptococcus*, while some unknown bacteria can also cause the intracranial infection. The global view of the bacterial composition can provide a better understanding of pathogens in PM, which can assist clinicians to make rational and effective therapeutic decisions to achieve maximum therapeutic effect in the treatment of PM in clinical practice.

Acknowledgments

This present work was funded by the National Natural Science Foundation of People's Republic of China (Grant Number: 81160151). The authors would like to thank Shenzhen Huada Gene Research Institute (Shenzhen, Guangdong, People's Republic of China) for technical assistance and sequencing services. Special thanks to Pingan Li, Yan Xie and David Leavesley for their proofreading of this manuscript.

Disclosure

The authors report no conflicts of interest in this work.

References

- Mann K, Jackson MA. Meningitis. *Pediatr Rev*. 2008;29(12):417–429; quiz 430.
- van de Beek D, de Gans J, Spanjaard L, Weisfelt M, Reitsma JB, Vermeulen M. Clinical features and prognostic factors in adults with bacterial meningitis. *N Engl J Med*. 2004;351(18):1849–1859.
- GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet*. 2015;385(9963):117–171.
- Scheld WM, Koedel U, Nathan B, Pfister HW. Pathophysiology of bacterial meningitis: mechanism(s) of neuronal injury. *J Infect Dis*. 2002;186(Suppl 2):S225–S233.
- Koedel U, Klein M, Pfister HW. New understandings on the pathophysiology of bacterial meningitis. *Curr Opin Infect Dis*. 2010;23(3):217–223.
- Thigpen MC, Whitney CG, Messonnier NE, et al. Bacterial meningitis in the United States, 1998–2007. *N Engl J Med*. 2011;364(21):2016–2025.
- Li Y, Yin Z, Shao Z, et al. Population-based surveillance for bacterial meningitis in China, September 2006–December 2009. *Emerg Infect Dis*. 2014;20(1):61–69.
- Sigauque B, Roca A, Sanz S, et al. Acute bacterial meningitis among children, in Manhica, a rural area in Southern Mozambique. *Acta Trop*. 2008;105(1):21–27.
- Bercion R, Bobossi-Serengbe G, Gody JC, et al. Acute bacterial meningitis at the 'Complexe Pediatrique' of Bangui, Central African Republic. *J Trop Pediatr*. 2008;54(2):125–128.
- Chaudhuri A. Adjunctive dexamethasone treatment in acute bacterial meningitis. *Lancet Neurol*. 2004;3(1):54–62.
- Ramakrishnan M, Ulland AJ, Steinhardt LC, Moïsi JC, Were F, Levine OS. Sequelae due to bacterial meningitis among African children: a systematic literature review. *BMC Med*. 2009;7:47.
- Pomar V, Martinez S, Paredes R, Domingo P. Advances in adjuvant therapy against acute bacterial meningitis. *Curr Drug Targets Infect Disord*. 2004;4(4):303–309.
- van de Beek D, Brouwer MC, Thwaites GE, Tunkel AR. Advances in treatment of bacterial meningitis. *Lancet*. 2012;380(9854):1693–1702.
- Brown RB, Sands M, Ryczak M. Community-acquired pneumonia caused by mixed aerobic bacteria. *Chest*. 1986;90(6):810–814.
- Takahashi T, Morozumi M, Chiba N, et al. Co-infection with respiratory syncytial virus subgroup a and *Streptococcus pneumoniae* detected by a comprehensive real-time polymerase chain reaction assay in an elderly patient with community-acquired pneumonia. *J Am Geriatr Soc*. 2009;57(9):1711–1713.
- Schlager R, Simmon KE, Fisher MA. A systematic approach for discovering novel, clinically relevant bacteria. *Emerg Infect Dis*. 2012;18(3):422–430.
- Bandara HM, Yau JY, Watt RM, Jin LJ, Samaranyake LP. *Pseudomonas aeruginosa* inhibits in-vitro *Candida* biofilm development. *BMC Microbiol*. 2010;10:125.
- van Belkum A. Molecular diagnostics in medical microbiology: yesterday, today and tomorrow. *Curr Opin Pharmacol*. 2003;3(5):497–501.
- Maibach RC, Dutly F, Altwegg M. Detection of *Tropheryma whipplei* DNA in feces by PCR using a target capture method. *J Clin Microbiol*. 2002;40(7):2466–2471.
- Woo PC, Tsoi HW, Leung KW, et al. Identification of *Mycobacterium neoaurum* isolated from a neutropenic patient with catheter-related bacteremia by 16S rRNA sequencing. *J Clin Microbiol*. 2000;38(9):3515–3517.
- Woo PC, Lau SK, Teng JL, Tse H, uen KY. Then and now: use of 16S rDNA gene sequencing for bacterial identification and discovery of novel bacteria in clinical microbiology laboratories. *Clin Microbiol Infect*. 2008;14(10):908–934.
- Ahmadian A, Gharizadeh B, Gustafsson AC, et al. Single-nucleotide polymorphism analysis by pyrosequencing. *Anal Biochem*. 2000;280(1):103–110.
- Sakamoto M, Umeda M, Ishikawa I, Benno Y. Comparison of the oral bacterial flora in saliva from a healthy subject and two periodontitis patients by sequence analysis of 16S rDNA libraries. *Microbiol Immunol*. 2000;44(8):643–652.
- Price LB, Liu CM, Melendez JH, et al. Community analysis of chronic wound bacteria using 16S rRNA gene-based pyrosequencing: impact of diabetes and antibiotics on chronic wound microbiota. *PLoS One*. 2009;4(7):e6462.
- Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. *PLoS Biol*. 2008;6(11):e280.
- Lyra A, Rinttila T, Nikkila J, et al. Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification. *World J Gastroenterol*. 2009;15(47):5936–5945.
- Fournier PE, Raoult D. Prospects for the future using genomics and proteomics in clinical microbiology. *Annu Rev Microbiol*. 2011;65:169–188.
- Siddiqui H, Nederbragt AJ, Lagesen K, Jeansson SL, Jakobsen KS. Assessing diversity of the female urine microbiota by high throughput sequencing of 16S rDNA amplicons. *BMC Microbiol*. 2011;11:244.
- Cole JR, Wang Q, Cardenas E, et al. The Ribosomal Database Project: improved alignments and new tools for rRNA analysis. *Nucleic Acids Res*. 2009;37(Database issue):D141–D145.
- Schloss PD, Westcott SL, Ryabin T, et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. *Appl Environ Microbiol*. 2009;75(23):7537–7541.
- Wang Q, Garrity GM, Tiedje JM, Cole JR. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. *Appl Environ Microbiol*. 2007;73(16):5261–5267.
- Rosen GL, Reichenberger ER, Rosenfeld AM. NBC: the Naive Bayes Classification tool webserver for taxonomic classification of metagenomic reads. *Bioinformatics*. 2011;27(1):127–129.
- Sogin ML, Morrison HG, Huber JA, et al. Microbial diversity in the deep sea and the underexplored "rare biosphere". *Proc Natl Acad Sci U S A*. 2006;103(32):12115–12120.
- McKenna P, Hoffmann C, Minkah N, et al. The macaque gut microbiome in health, lentiviral infection, and chronic enterocolitis. *PLoS Pathog*. 2008;4(2):e20.
- Simon C, Daniel R. Metagenomic analyses: past and future trends. *Appl Environ Microbiol*. 2011;77(4):1153–1161.
- van Driel JJ, Bekker V, Spanjaard L, van der Ende A, Kuijpers TW. Epidemiologic and microbiologic characteristics of recurrent bacterial and fungal meningitis in the Netherlands, 1988–2005. *Clin Infect Dis*. 2008;47(5):e42–e51.
- Boque MC, Bodi M, Rello J. Trauma, head injury, and neurosurgery infections. *Semin Respir Infect*. 2000;15(4):280–286.

38. Armougom F, Bittar F, Stremler N, et al. Microbial diversity in the sputum of a cystic fibrosis patient studied with 16S rDNA pyrosequencing. *Eur J Clin Microbiol Infect Dis*. 2009;28(9):1151–1154.
39. RodriguezGuardado A, Blanco A, Asensi V, et al. Multidrug-resistant *Acinetobacter meningitis* in neurosurgical patients with intraventricular catheters: assessment of different treatments. *J Antimicrob Chemother*. 2008; 61(4):908–913.
40. Parda N, Polkowska A. [Meningitis and encephalitis in Poland in 2010]. *Przegl Epidemiol*. 2012;66(2):221–228.
41. Butsashvili M, Kandelaki G, Eloshvili M, Chlikadze R, Imnadze P, Avaliani N. Surveillance of bacterial meningitis in the country of Georgia, 2006–2010. *J Community Health*. 2013;38(4):724–726.
42. Dzapová O, Polivkova S, Smiskova D, Benes J. [Epidemiological, clinical and laboratory characteristics of bacterial meningitis in adult patients]. *Klin Mikrobiol Infekc Lek*. 2010;16(2):58–63.
43. Azevedo LC, Toscano CM, Bierrenbach AL. Bacterial meningitis in Brazil: baseline epidemiologic assessment of the decade prior to the introduction of pneumococcal and meningococcal vaccines. *PLoS One*. 2013;8(6):e64524.
44. Mendsaikhan J, Watt JP, Mansoor O, et al. Childhood bacterial meningitis in Ulaanbaatar, Mongolia, 2002–2004. *Clin Infect Dis*. 2009; 48(Suppl 2):S141–S146.
45. Teleb N, Pilishvili T, Van Beneden C, et al. Bacterial meningitis surveillance in the Eastern Mediterranean region, 2005–2010: successes and challenges of a regional network. *J Pediatr*. 2013;163(1 Suppl): S25–S31.
46. Centers for Disease Control and Prevention. Pediatric bacterial meningitis surveillance – African region, 2002–2008. *MMWR Morb Mortal Wkly Rep*. 2009;58(18):493–497.
47. Dash N, Panigrahi D, Al Khusaiby S, Al Awaidy S, Bawikar S. Acute bacterial meningitis among children <5 years of age in Oman: a retrospective study during 2000–2005. *J Infect Dev Ctries*. 2008;2(2): 112–115.
48. Kaijalainen T, Kharit SM, Kvetnaya AS, et al. Invasive infections caused by *Neisseria meningitidis*, *Haemophilus influenzae* and *Streptococcus pneumoniae* among children in St Petersburg, Russia. *Clin Microbiol Infect*. 2008;14(5):507–510.
49. Cho HK, Lee H, Kang JH, et al. The causative organisms of bacterial meningitis in Korean children in 1996–2005. *J Korean Med Sci*. 2010; 25(6):895–899.
50. Pérez AE, Dickinson FO, Rodriguez M. Community acquired bacterial meningitis in Cuba: a follow up of a decade. *BMC Infect Dis*. 2010;10: 130.

Drug Design, Development and Therapy

Dovepress

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which

has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/drug-design-development-and-therapy-journal>